- Home
- IGMS vs CTOR Comparison
IGMS vs CTOR Comparison
Compare IGMS & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- CTOR
- Stock Information
- Founded
- IGMS 1993
- CTOR 2021
- Country
- IGMS United States
- CTOR United States
- Employees
- IGMS N/A
- CTOR N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- CTOR
- Sector
- IGMS Health Care
- CTOR
- Exchange
- IGMS Nasdaq
- CTOR NYSE
- Market Cap
- IGMS 82.1M
- CTOR 89.9M
- IPO Year
- IGMS 2019
- CTOR N/A
- Fundamental
- Price
- IGMS $1.24
- CTOR $0.67
- Analyst Decision
- IGMS Hold
- CTOR Strong Buy
- Analyst Count
- IGMS 8
- CTOR 2
- Target Price
- IGMS $6.14
- CTOR $4.50
- AVG Volume (30 Days)
- IGMS 198.4K
- CTOR 166.3K
- Earning Date
- IGMS 03-06-2025
- CTOR 05-21-2025
- Dividend Yield
- IGMS N/A
- CTOR N/A
- EPS Growth
- IGMS N/A
- CTOR N/A
- EPS
- IGMS N/A
- CTOR N/A
- Revenue
- IGMS $2,679,000.00
- CTOR N/A
- Revenue This Year
- IGMS $134.71
- CTOR N/A
- Revenue Next Year
- IGMS $74.27
- CTOR N/A
- P/E Ratio
- IGMS N/A
- CTOR N/A
- Revenue Growth
- IGMS 25.77
- CTOR N/A
- 52 Week Low
- IGMS $1.15
- CTOR $0.55
- 52 Week High
- IGMS $22.50
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- IGMS 37.38
- CTOR N/A
- Support Level
- IGMS $1.17
- CTOR N/A
- Resistance Level
- IGMS $1.31
- CTOR N/A
- Average True Range (ATR)
- IGMS 0.09
- CTOR 0.00
- MACD
- IGMS 0.05
- CTOR 0.00
- Stochastic Oscillator
- IGMS 32.14
- CTOR 0.00
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.